{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:41:23Z","timestamp":1783597283351,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Intramural Research Program, National Institutes of Neurological Disorders and Stroke"},{"name":"Intramural Research Program, National Cancer Institute"},{"name":"Intramural Research Program, National Institute on Deafness and Other Communication Disorders"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Xeroderma pigmentosum (XP) is a rare autosomal recessive genetic disorder with defective DNA nucleotide excision repair and associated with a high frequency of skin cancer. Approximately 25% of patients develop progressive neurological degeneration. Complementation groups XP-A and XP-D are most frequently associated with neurological disorders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design\/methods<\/jats:title>\n                <jats:p>This is a retrospective review of patients with XP who were evaluated at NIH from 1986 to 2015 and had nerve conduction studies (NCS). In the complementation groups with peripheral neuropathy, further comparisons of the NCS were made with audiological, brain imaging, neuropsychological assessments that were also performed on most of the patients. Limited neuropathology of XP-A and XP-D patients were examined..<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 33 patients had NCS: XP-A (9 patients), XP-C (7 patients), XP-D (10 patients), XP-E (1 patient), XP-V (4 patients), and XP-unknown (2 patients). Peripheral neuropathy based on nerve conduction studies was documented only in two complementation groups: 78% (7\/9) of XP-A patients had a sensorimotor neuropathy while 50% (5\/10) of XP-D patients had a sensory neuropathy only. Analysis of sural sensory nerve amplitude in both complementation groups XP-A and XP-D correlated with sensorineural hearing loss (SNHL), MRI\/CT severity, and Full-scale Intelligence Quotient (IQ). Analysis of fibular motor nerve amplitude in complementation XP-A correlated with SNHL and MRI\/CT severity. Limited follow-up studies showed gradual loss of NCS responses compared to an earlier and more rapid progression of the hearing loss.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite similar brain imaging and audiological findings patients, XP-A and XP-D complementation groups differ in the type of neuropathy, sensorimotor versus sensory alone. A few cases suggest that sensorineural hearing loss may precede abnormal NCS in XP and therefore serve as valuable clinical indicators of XP patients that will later develop peripheral neuropathy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02414-2","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:05:27Z","timestamp":1633896327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differences in peripheral neuropathy in xeroderma pigmentosum complementation groups A and D as evaluated by nerve conduction studies"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-505X","authenticated-orcid":false,"given":"Tanya J.","family":"Lehky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sackstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikandar G.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Patronas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edythe","family":"Wiggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen C.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"DiGiovanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"2414_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/jid.2011.426","volume":"132","author":"JJ DiGiovanna","year":"2012","unstructured":"DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol. 2012;132:785\u201396.","journal-title":"J Invest Dermatol"},{"key":"2414_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.lfs.2017.12.035","volume":"195","author":"B Bukowska","year":"2018","unstructured":"Bukowska B, Karwowski BT. Actual state of knowledge in the field of diseases related with defective nucleotide excision repair. Life Sci. 2018;195:6\u201318.","journal-title":"Life Sci"},{"key":"2414_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/ejpn.2001.0523","volume":"5","author":"Y Lindenbaum","year":"2001","unstructured":"Lindenbaum Y, Dickson D, Rosenbaum P, Kraemer K, Robbins I, Rapin I. Xeroderma pigmentosum\/cockayne syndrome complex: first neuropathological study and review of eight other cases. Eur J Paediatr Neurol. 2001;5:225\u201342.","journal-title":"Eur J Paediatr Neurol"},{"key":"2414_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2051-5960-1-4","volume":"1","author":"JP Lai","year":"2013","unstructured":"Lai JP, Liu YC, Alimchandani M, et al. The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathol Commun. 2013;1:4.","journal-title":"Acta Neuropathol Commun"},{"key":"2414_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/brain\/aws317","volume":"136","author":"MB Totonchy","year":"2013","unstructured":"Totonchy MB, Tamura D, Pantell MS, et al. Auditory analysis of xeroderma pigmentosum 1971-2012: hearing function, sun sensitivity and DNA repair predict neurological degeneration. Brain. 2013;136:194\u2013208.","journal-title":"Brain"},{"key":"2414_CR6","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/brain\/awn126","volume":"131","author":"A Anttinen","year":"2008","unstructured":"Anttinen A, Koulu L, Nikoskelainen E, et al. Neurological symptoms and natural course of xeroderma pigmentosum. Brain. 2008;131:1979\u201389.","journal-title":"Brain"},{"key":"2414_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2017.08.3238","volume":"381","author":"T Ueda","year":"2017","unstructured":"Ueda T, Kanda F, Nishiyama M, Nishigori C, Toda T. Quantitative analysis of brain atrophy in patients with xeroderma pigmentosum group a carrying the founder mutation in Japan. J Neurol Sci. 2017;381:103\u20136.","journal-title":"J Neurol Sci"},{"key":"2414_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.22","volume":"2","author":"T Ueda","year":"2012","unstructured":"Ueda T, Kanda F, Aoyama N, Fujii M, Nishigori C, Toda T. Neuroimaging features of xeroderma pigmentosum group a. Brain Behav. 2012;2:1\u20135.","journal-title":"Brain Behav"},{"key":"2414_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1097\/MAO.0b013e31829795e9","volume":"34","author":"LM Viana","year":"2013","unstructured":"Viana LM, Seyyedi M, Brewer CC, et al. Histopathology of the inner ear in patients with xeroderma pigmentosum and neurologic degeneration. Otol Neurotol. 2013;34:1230\u20136.","journal-title":"Otol Neurotol"},{"key":"2414_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ophtha.2012.12.044","volume":"120","author":"BP Brooks","year":"2013","unstructured":"Brooks BP, Thompson AH, Bishop RJ, et al. Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage. Ophthalmology. 2013;120:1324\u201336.","journal-title":"Ophthalmology"},{"key":"2414_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jid.2017.08.046","volume":"138","author":"E Nakano","year":"2018","unstructured":"Nakano E, Takeuchi S, Ono R, Tsujimoto M, Masaki T, Nishigori C. Xeroderma Pigmentosum diagnosis using a flow Cytometry-based nucleotide excision repair assay. J Invest Dermatol. 2018;138:467\u201370.","journal-title":"J Invest Dermatol"},{"key":"2414_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.survophthal.2011.03.001","volume":"56","author":"HL Ramkumar","year":"2011","unstructured":"Ramkumar HL, Brooks BP, Cao X, et al. Ophthalmic manifestations and histopathology of xeroderma pigmentosum: two clinicopathological cases and a review of the literature. Surv Ophthalmol. 2011;56:348\u201361.","journal-title":"Surv Ophthalmol"},{"key":"2414_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archdermatol.2009.279","volume":"145","author":"S Christen-Zaech","year":"2009","unstructured":"Christen-Zaech S, Imoto K, Khan SG, et al. Unexpected occurrence of xeroderma pigmentosum in an uncle and nephew. Arch Dermatol. 2009;145:1285\u201391.","journal-title":"Arch Dermatol"},{"key":"2414_CR14","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1084\/jem.20091892","volume":"206","author":"T Ueda","year":"2009","unstructured":"Ueda T, Compe E, Catez P, Kraemer KH, Egly JM. Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients. J Exp Med. 2009;206:3031\u201346.","journal-title":"J Exp Med"},{"key":"2414_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/ejhg.2012.246","volume":"21","author":"X Zhou","year":"2013","unstructured":"Zhou X, Khan SG, Tamura D, et al. Abnormal XPD-induced nuclear receptor transactivation in DNA repair disorders: trichothiodystrophy and xeroderma pigmentosum. Eur J Hum Genet. 2013;21:831\u20137.","journal-title":"Eur J Hum Genet"},{"key":"2414_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mus.880131002","volume":"13","author":"PD Donofrio","year":"1990","unstructured":"Donofrio PD, Albers JW. AAEM minimonograph #34: polyneuropathy: classification by nerve conduction studies and electromyography. Muscle Nerve. 1990;13:889\u2013903.","journal-title":"Muscle Nerve"},{"key":"2414_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/mus.27028","volume":"62","author":"Y Tsuji","year":"2020","unstructured":"Tsuji Y, Ueda T, Sekiguchi K, et al. Progressive length-dependent polyneuropathy in xeroderma pigmentosum group a. Muscle Nerve. 2020;62:534\u201340.","journal-title":"Muscle Nerve"},{"issue":"Pt 4","key":"2414_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/brain\/113.4.1025","volume":"113","author":"T Kanda","year":"1990","unstructured":"Kanda T, Oda M, Yonezawa M, et al. Peripheral neuropathy in xeroderma pigmentosum. Brain. 1990;113(Pt 4):1025\u201344.","journal-title":"Brain"},{"key":"2414_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/088307388800300207","volume":"3","author":"N Tachi","year":"1988","unstructured":"Tachi N, Sasaki K, Kusano T, et al. Peripheral neuropathy in four cases of group a xeroderma pigmentosum. J Child Neurol. 1988;3:114\u20139.","journal-title":"J Child Neurol"},{"key":"2414_CR20","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/nn.3537","volume":"16","author":"PJ McKinnon","year":"2013","unstructured":"McKinnon PJ. Maintaining genome stability in the nervous system. Nat Neurosci. 2013;16:1523\u20139.","journal-title":"Nat Neurosci"},{"issue":"Pt 1","key":"2414_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3280001","volume":"328","author":"JE Cleaver","year":"1997","unstructured":"Cleaver JE, States JC. The DNA damage-recognition problem in human and other eukaryotic cells: the XPA damage binding protein. Biochem J. 1997;328(Pt 1):1\u201312.","journal-title":"Biochem J"},{"key":"2414_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.cell.2008.04.029","volume":"133","author":"H Liu","year":"2008","unstructured":"Liu H, Rudolf J, Johnson KA, et al. Structure of the DNA repair helicase XPD. Cell. 2008;133:801\u201312.","journal-title":"Cell"},{"key":"2414_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcdb.2020.10.009","volume":"114","author":"GS Kajitani","year":"2021","unstructured":"Kajitani GS, Nascimento LLS, Neves MRC, Leandro GDS, Garcia CCM, Menck CFM. Transcription blockage by DNA damage in nucleotide excision repair-related neurological dysfunctions. Semin Cell Dev Biol. 2021;114:20\u201335.","journal-title":"Semin Cell Dev Biol"},{"key":"2414_CR24","doi-asserted-by":"publisher","first-page":"4654206","DOI":"10.1155\/2019\/4654206","volume":"2019","author":"F Kobaisi","year":"2019","unstructured":"Kobaisi F, Fayyad N, Rezvani HR, et al. Signaling pathways, chemical and biological modulators of nucleotide excision repair: the faithful shield against uv genotoxicity. Oxid Med Cell Longev. 2019;2019:4654206.","journal-title":"Oxid Med Cell Longev"},{"key":"2414_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.mrrev.2014.12.002","volume":"763","author":"BC Feltes","year":"2015","unstructured":"Feltes BC, Bonatto D. Overview of xeroderma pigmentosum proteins architecture, mutations and post-translational modifications. Mutat Res Rev Mutat Res. 2015;763:306\u201320.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"2414_CR26","doi-asserted-by":"publisher","unstructured":"Rizza ERH, DiGiovanna JJ, Khan SG, Tamura D, Jeskey JD, Kraemer KH. Xeroderma Pigmentosum: a model for human premature aging. J Invest Dermatol. 2021 Apr;141(4S):976-984. https:\/\/doi.org\/10.1016\/j.jid.2020.11.012. Epub 2021 Jan 9.PMID: 33436302","DOI":"10.1016\/j.jid.2020.11.012"},{"key":"2414_CR27","doi-asserted-by":"publisher","first-page":"102937","DOI":"10.1016\/j.dnarep.2020.102937","volume":"94","author":"AM de Sousa Leal","year":"2020","unstructured":"de Sousa Leal AM, de Azevedo Medeiros LB, Munoz-Cadavid CO, et al. XPA deficiency affects the ubiquitin-proteasome system function. DNA Repair (Amst). 2020;94:102937.","journal-title":"DNA Repair (Amst)"},{"key":"2414_CR28","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1021\/tx300351p","volume":"25","author":"N Kamakura","year":"2012","unstructured":"Kamakura N, Yamamoto J, Brooks PJ, Iwai S, Kuraoka I. Effects of 5\u2032,8-cyclodeoxyadenosine triphosphates on DNA synthesis. Chem Res Toxicol. 2012;25:2718\u201324.","journal-title":"Chem Res Toxicol"},{"key":"2414_CR29","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.dnarep.2008.03.016","volume":"7","author":"PJ Brooks","year":"2008","unstructured":"Brooks PJ. The 8,5\u2032-cyclopurine-2\u2032-deoxynucleosides: candidate neurodegenerative DNA lesions in xeroderma pigmentosum, and unique probes of transcription and nucleotide excision repair. DNA Repair (Amst). 2008;7:1168\u201379.","journal-title":"DNA Repair (Amst)"},{"key":"2414_CR30","doi-asserted-by":"publisher","first-page":"22355","DOI":"10.1074\/jbc.M002259200","volume":"275","author":"PJ Brooks","year":"2000","unstructured":"Brooks PJ, Wise DS, Berry DA, et al. The oxidative DNA lesion 8,5\u2032-(S)-cyclo-2\u2032-deoxyadenosine is repaired by the nucleotide excision repair pathway and blocks gene expression in mammalian cells. J Biol Chem. 2000;275:22355\u201362.","journal-title":"J Biol Chem"},{"key":"2414_CR31","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1073\/pnas.070471597","volume":"97","author":"I Kuraoka","year":"2000","unstructured":"Kuraoka I, Bender C, Romieu A, Cadet J, Wood RD, Lindahl T. Removal of oxygen free-radical-induced 5\u2032,8-purine cyclodeoxynucleosides from DNA by the nucleotide excision-repair pathway in human cells. Proc Natl Acad Sci U S A. 2000;97:3832\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2414_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.freeradbiomed.2016.12.028","volume":"107","author":"PJ Brooks","year":"2017","unstructured":"Brooks PJ. The cyclopurine deoxynucleosides: DNA repair, biological effects, mechanistic insights, and unanswered questions. Free Radic Biol Med. 2017;107:90\u2013100.","journal-title":"Free Radic Biol Med"},{"key":"2414_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/cbin.10917","volume":"42","author":"M Prates Mori","year":"2018","unstructured":"Prates Mori M, de Souza-Pinto NC. Role of mitochondrial dysfunction in the pathophysiology of DNA repair disorders. Cell Biol Int. 2018;42:643\u201350.","journal-title":"Cell Biol Int"},{"key":"2414_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s13238-016-0244-y","volume":"7","author":"L Fu","year":"2016","unstructured":"Fu L, Xu X, Ren R, et al. Modeling xeroderma pigmentosum associated neurological pathologies with patients-derived iPSCs. Protein Cell. 2016;7:210\u201321.","journal-title":"Protein Cell"},{"key":"2414_CR35","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1111\/bph.14557","volume":"176","author":"R Abeti","year":"2019","unstructured":"Abeti R, Zeitlberger A, Peelo C, et al. Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms. Br J Pharmacol. 2019;176:4293\u2013301.","journal-title":"Br J Pharmacol"},{"key":"2414_CR36","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/bcp.12928","volume":"82","author":"C Evangelisti","year":"2016","unstructured":"Evangelisti C, Cenni V, Lattanzi G. Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders. Br J Clin Pharmacol. 2016;82:1229\u201344.","journal-title":"Br J Clin Pharmacol"},{"key":"2414_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bjd.17253","volume":"181","author":"JL Weon","year":"2019","unstructured":"Weon JL, Glass DA 2nd. Novel therapeutic approaches to xeroderma pigmentosum. Br J Dermatol. 2019;181:249\u201355.","journal-title":"Br J Dermatol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02414-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:15:45Z","timestamp":1633896945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02414-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2414"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02414-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"17 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients were evaluated under clinical protocols, NCT00001813 and NCT00046189, approved by the National Institutes of Health (NIH) Institutional Review Boards. Written, informed consent and assent, was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Included in consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial disclosures or other conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"393"}}